Clemens Gießen-Jung

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius et al. · The Lancet Oncology · 2016 · 410 citations

Cetuximab Versus Folfiri, Gastrointestinal Oncology, Tumour Dynamics +10

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Dominik Paul Modest, Ingrid Ricard, Volker Heinemann et al. · Annals of Oncology · 2016 · 334 citations · Full text

Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis?

Jan‐Niclas Mumm, Andreas Osterman, Michael Ruzicka et al. · European Urology · 2020 · 145 citations · Full text

Urinary Frequency, Urological Research, Urology +6

Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients

Dieter Munker, Andreas Osterman, Hans Stubbe et al. · European Respiratory Journal · 2021 · 92 citations · Full text

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study—XELAVIRI (AIO KRK0110)

Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker et al. · Journal of Clinical Oncology · 2018 · 47 citations